Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety

#Cancer #Kanser #MemeKanseri #BreastCancer #Alpelisib #Elacestrant #MedSky #Sage

journals.sagepub.com/doi/10.1177/...

Alpesib 150 mg (Alpelisib) | Online International Pharmacy Alpesib 150 mg (Alpelisib) is used to treat advanced breast cancer by inhibiting PI3K, a key cancer cell growth signaling pathway.

Alpesib 150 mg (Alpelisib) is a targeted therapy used in combination with other treatments for advanced breast cancer, specifically in patients with PIK3CA mutations, by inhibiting the PI3K pathway.
#Alpesib150mg #Alpelisib #OnlineMedicine #Oncology #Health
jnspharma.com/product/alpe...

Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety - Ünal Metin Tokat, Şevval Nur Bi... Breast cancer (BC) is the leading cause of cancer-related mortality among women, and hormone receptor (HR)-positive subtype makes up the majority of all cases. ...

"Here we showed for the first time that an all-oral combination of elacestrant plus alpelisib was feasible, tolerable, and clinically active in an ESR1 and PIK3CA co-mutated and heavily pretreated patient."

#BreastCancer #MemeKanseri #Elacestrant #Alpelisib

Nicholas Robert: Community Oncology Is Driving the Future of Cancer Research - OncoDaily Nicholas Robert: Community Oncology Is Driving the Future of Cancer Research / alpelisib, Azure OpenAI Global Batch, biomarker testing, cancer, Cancer

Community Oncology Is Driving the Future of Cancer Research - Nicholas Robert

oncodaily.com/insight/nich...

fda.gov

#Alpelisib #AzureOpenAIGlobalBatch #BiomarkerTesting #Cancer #CancerResearch #CancerTreatment #FDA #iKnowMed #OncoDaily #Oncology